Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Simcere Pharma (2096 HK): Sanbexin Increase Market Share; Prospective Pipeline, Approvals Holds Key

Simcere Pharmaceutical (2096 HK) Placement: Innovative Pipeline Enlightens Growth Prospects

Simcere Pharma (2096 HK): Proposed Spin-Off Will Unlock Value and Open Funding Avenues for Zaiming

Simcere Pharma (2096 HK): Agreement With Vigonvita Positive, Pipeline and Approvals Key Strength

Equity Bottom-Up

Simcere Pharmaceutical / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/simcere-pharmaceutical-group" target="_blank" data-smartkarma-citation="entities:29186:1" rel="noopener">Simcere Pharmaceutical Group (2096 HK)</a> reported 16% YoY revenue growth to RMB 7.7B, driven by a 28% YoY growth in revenue from the innovative pharmaceutical business.</li>
<li>Sanbexin injection, company’s flagship product, accounted for approximately 31% of the market share (29% in 1H25) in stroke injection, covering approximately 0.41M patients.</li>
<li>The extensive pipeline reserves have huge clinical and commercialization potential. Licensing deals signed alongside strong innovative drug portfolio, approvals and promising future pipeline augur well for future growth.</li>
</ul>



Simcere Pharmaceutical Group (2096 HK) reported 16% YoY revenue growth to RMB 7.7B, driven by a 28% YoY growth in revenue from the innovative pharmaceutical business.
Sanbexin injection, company’s flagship product, accounted for approximately 31% of the market share (29% in 1H25) in stroke injection, covering approximately 0.41M patients.
The extensive pipeline reserves have huge clinical and commercialization potential. Licensing deals signed alongside strong innovative drug portfolio, approvals and promising future pipeline augur well for future growth.


Simcere Pharma (2096 HK): Sturdy 2025; Promising Pipeline, Approvals Will Take It Forward